Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax, Novavax, and Inovio Stocks Sank This Week

By Keith Speights – Aug 20, 2021 at 6:04AM

Key Points

  • The U.S. Department of Health and Human Services announced plans to begin giving third booster doses of messenger RNA vaccines on Sept. 20.
  • This decision could reduce the likelihood that the U.S. will purchase doses from COVID-19 vaccines that could be authorized in the not-too-distant future.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.

What happened

Shares of several companies involved in the development of COVID-19 vaccines sank this week. As of the market close on Thursday, Dynavax Technologies (DVAX 1.44%) stock had dropped 12%, and shares of Novavax (NVAX -1.96%) and Inovio Pharmaceuticals (INO 3.12%) were down 15.5% and 15.8%, respectively.

None of these companies announced any news this week. Instead, the stocks likely fell due to the decision by the Biden administration to push for third booster doses of messenger RNA (mRNA) vaccines made by Pfizer-BioNTech and Moderna. This move could increase the uncertainty about the future for COVID-19 vaccines that haven't yet reached the market.

An image  of the earth inside an image of the coronavirus.

Image source: Getty Images.

So what

Vaccine stocks, especially those of companies that don't have COVID-19 vaccines on the market, already tend to be highly volatile. The White House announcement this week about moving forward with third booster doses for mRNA vaccines only added to this volatility.

The U.S. Department of Health and Human Services (HHS) stated on Wednesday that booster shots for all Americans who have received the Pfizer-BioNTech and Moderna COVID-19 vaccines will begin the week of Sept. 30, 2021, pending completion of a review by the Food and Drug Administration (FDA). These third booster doses will be given eight months after an individual's second dose of the mRNA vaccines.

HHS also said that booster shots are anticipated for individuals who received Johnson & Johnson's COVID-19 vaccine. However, the agency stated that more data is expected within the next few weeks.

No one knows at this point how long any additional protection from booster doses will last. But the longer the period of immunity, the less likely doses of other vaccines that become available will be needed.

That's potentially bad news for Dynavax, Novavax, and Inovio. Dynavax's CpG 1018 adjuvant is being used in several experimental COVID-19 vaccines in development. Novavax plans to file for Emergency Use Authorization (EUA) in multiple countries over the next several months. Inovio and its partner Advaccine are evaluating the company's COVID-19 vaccine candidate in a global phase 3 study.

Now what

The booster-dose news seemed to rattle investors who are cheering for Dynavax, Novavax, and Inovio. However, there are much more important potential catalysts for these stocks.

Dynavax expects several clinical updates from its collaboration partners that use Cpg 1018. The company believes that these could set the stage for EUA or conditional authorization by the end of this year.

Novavax has already filed for EUA for its COVID-19 vaccine with its partner, Serum Institute of India, in India, Indonesia, and the Philippines. The company intends to submit EUAs in several other countries, including the U.K., European Union, and the U.S., in the third and fourth quarters of this year.

Inovio is focusing primarily on non-U.S. markets with its COVID-19 program for now. However, CEO Joseph Kim said in Inovio's Q2 conference call that the company will talk with the FDA about lifting the partial clinical hold on its COVID-19 vaccine studies after efficacy is demonstrated in its global late-stage study. 

Keith Speights owns shares of Pfizer. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.98 (3.12%) $0.06
Dynavax Technologies Stock Quote
Dynavax Technologies
DVAX
$12.72 (1.44%) $0.18
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.88 (0.08%) $0.14
Pfizer Stock Quote
Pfizer
PFE
$50.91 (-0.33%) $0.17
Novavax Stock Quote
Novavax
NVAX
$16.52 (-1.96%) $0.33
Moderna Stock Quote
Moderna
MRNA
$182.35 (0.48%) $0.87
BioNTech Se Stock Quote
BioNTech Se
BNTX
$169.74 (0.16%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.